Skip to search formSkip to main contentSkip to account menu

AZD 6244

Known as: AZD-6244, AZD6244, MEK inhibitor AZD6244 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (2)

ARRY 142886selumetinib

Broader (1)

Benzimidazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify… 
2016
2016
SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
10503Background: PN in NF1 can cause substantial morbidity, and there are no approved medical therapies. In a phase I trial of… 
2015
2015
Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor…
2015
2015
Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer
PTEN deletion, mutation or reduced expression occurs in 63% of metastatic prostate tumors, resulting in the activation of PI3K… 
2014
2014
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS‐mutant melanoma
The MEK inhibitor MEK162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS… 
2014
2014
Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
10018 Background: Lack of functional neurofibromin in NF1 leads to dysregulated Ras and tumorigenesis. Selumetinib (AZD6244; ARRY… 
Highly Cited
2013
Highly Cited
2013
Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Purpose: Results from clinical trials involving resistance to molecularly targeted therapies have revealed the importance of… 
2011
2011
Actin and ERK1/2-CEBPβ signaling mediates phagocytosis-induced innate immune response of osteoprogenitor cells.
Highly Cited
2010
Highly Cited
2010
Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines
Selumetinib (AZD6244; ARRY-142886) is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK… 
2009
2009
Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models
The ERK and mTOR pathways show multiple interconnections that coordinate growth activation and the regulation of protein… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)